PRODIGE 4 / ACCORD 11
FOLFIRINOX in Metastatic Pancreatic Cancer
Paciente / Población Intervención / Exposición Comparación Desenlace
In 342 patients with metastatic pancreatic adenocarcinoma, ECOG 0–1, age ≤75, FOLFIRINOX improved overall survival compared with gemcitabine.
N
342
Diseño
Phase 2/3 RCT
Desenlace
Overall survival
Relevancia
2
ResultadoOS 11.1 vs 6.8 months (HR 0.57). PFS HR 0.47; ORR 31.6% vs 9.4%; more grade 3/4 toxicity but better QoL maintenance.
Conroy T, et al. N Engl J Med. 2011;364(19):1817-1825. 10.1056/NEJMoa1011923
Discusión y crítica
Most active regimen in fit metastatic-pancreatic patients; later extended to the adjuvant setting (PRODIGE 24). Reserve for ECOG 0–1.